Lupin obtains FDA OK for generic Vibramycin
Doxycycline for Injection is indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline and other antibacterial drugs.
Lupin has received the Food and Drug Administration’s permission for Doxycycline for Injection, 100 mg/Vial (Single-Dose Vial), which is the generic of Pfizer’s Vibramycin.
The product will be manufactured at Lupin’s Nagpur facility in India.
Doxycycline for Injection is indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline and other antibacterial drugs. Doxycycline for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Doxycycline for Injection (RLD Vibramycin) had a market value of approximately $47 million, per IQVIA January 2024 data.